Home > Publications database > Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2 > print

001     285675
005     20240328112643.0
024 7 _ |a 10.3389/fimmu.2023.1272018
|2 doi
024 7 _ |a altmetric:156278593
|2 altmetric
037 _ _ |a DKFZ-2023-02497
082 _ _ |a 610
100 1 _ |a Mariz, Filipe Colaco
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2
260 _ _ |a Lausanne
|c 2023
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1711621580_3151
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:F035#LA:F035# / EMBL-DKFZ Chemical Biology Core Facility
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: inrepo02.dkfz.de
700 1 _ |a Putzker, Kerstin
|0 P:(DE-He78)04eb74f47fce0fa7e60ef3880ee01ada
|b 1
|u dkfz
700 1 _ |a Sehr, Peter
|0 P:(DE-He78)219d54a7bf634121fbf16bea82d434e1
|b 2
|u dkfz
700 1 _ |a Müller, Martin
|0 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579
|b 3
|e Last author
|u dkfz
773 _ _ |a 10.3389/fimmu.2023.1272018
|g Vol. 14, p. 1272018
|0 PERI:(DE-600)2606827-8
|p 1272018
|t Frontiers in immunology
|v 14
|y 2023
|x 1664-3224
909 C O |p VDB
|o oai:inrepo02.dkfz.de:285675
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)04eb74f47fce0fa7e60ef3880ee01ada
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)219d54a7bf634121fbf16bea82d434e1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
914 1 _ |y 2023
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT IMMUNOL : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-11T10:28:02Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-11T10:28:02Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2021-05-11T10:28:02Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-05-11T10:28:02Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-26
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT IMMUNOL : 2022
|d 2023-10-26
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-26
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-26
920 2 _ |0 I:(DE-He78)F035-20160331
|k F035
|l Tumorvirus-spez. Vakzinierungsstrategie
|x 0
920 1 _ |0 I:(DE-He78)F035-20160331
|k F035
|l Tumorvirus-spez. Vakzinierungsstrategie
|x 0
920 1 _ |0 I:(DE-He78)W040-20160331
|k W040
|l Gruppe Sehr EMBL
|x 1
920 0 _ |0 I:(DE-He78)F035-20160331
|k F035
|l Tumorvirus-spez. Vakzinierungsstrategie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F035-20160331
980 _ _ |a I:(DE-He78)W040-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21